Evidence map›Paper›PMID 40317903›Full record

ArticleActa ophthalmologica2025

Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy.

F M van den Tillaart, A Komrojan, C B Hoyng, J P Martinez Ciriano, S Yzer

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

F M van den TillaartDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-0583-2450
A KomrojanDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
C B HoyngDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
J P Martinez CirianoRotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, The Netherlands.
S YzerDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

Stichting A.F. Deutman Oogheelkunde ResearchfondsStichting Steunfonds Uitzicht 2021-15Stichting voor Ooglijders
6 · The paper itself

Abstract

purposeTo evaluate anatomical and functional outcomes after a second photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC), who had a recurrence of subretinal fluid (SRF) after a previously successful PDT.

methodsIn this multicentre retrospective cohort study, we included patients with CSC who underwent a second PDT because of a recurrence of SRF after an effective first PDT with complete SRF resolution. Diagnosis of CSC was based on multimodal imaging. We evaluated the complete resolution rate of SRF after a second PDT with reduced settings. Also, visual acuity (VA), subfoveal ellipsoid zone (EZ) and subfoveal external limiting membrane (ELM) integrity before and after the first and the second PDT were studied.

resultsA total of 88 patients were studied, of whom 18% were female. The mean age was 51.3 ± 10.5 years at the second PDT. At the first follow-up visit after the second PDT (median of 44 days [IQR 40-51] after PDT), a complete resolution of SRF occurred in 64% of eyes. The median VA was 0.15 LogMAR before the second PDT and improved to 0.05 LogMAR (p < 0.001) after PDT. The EZ was continuous in 3% of patients before the second PDT, and EZ continuity increased to 27% at the first follow-up visit after PDT. No new atrophy was observed after the second PDT.

conclusionA second PDT with reduced settings in recurrent CSC is effective and safe in the short term, as significant anatomical and functional improvement was observed.

Indexed as

Central Serous ChorioretinopathyPhotochemotherapyVerteporfinVisual AcuityAdultFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansMaleMiddle AgedPhotosensitizing AgentsRecurrenceRetrospective StudiesSubretinal FluidPhotosensitizing AgentsVerteporfincentral serous chorioretinopathymultimodal imagingphotodynamic therapyrecurrencerepeated photodynamic therapysubretinal fluid

Identifiers

PMID40317903
PMCPMC12531609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.